These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


161 related items for PubMed ID: 7767948

  • 1. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB, Boeve TJ, Hande KR.
    Cancer Chemother Pharmacol; 1995; 36(2):125-8. PubMed ID: 7767948
    [Abstract] [Full Text] [Related]

  • 2. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH.
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [Abstract] [Full Text] [Related]

  • 3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE, Relling MV.
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [Abstract] [Full Text] [Related]

  • 4. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
    Kronbach T.
    Methods Enzymol; 1991 Dec; 206():509-17. PubMed ID: 1686064
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
    Jaruratanasirikul S, Cooper AD, Blaschke TF.
    Drug Metab Dispos; 1992 Dec; 20(3):379-82. PubMed ID: 1355711
    [Abstract] [Full Text] [Related]

  • 6. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR, Gorski JC, Haehner BD, O'Mara EM, Hall SD.
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [Abstract] [Full Text] [Related]

  • 7. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, Eichelbaum M, Jaillon P, Funck-Brentano C.
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [Abstract] [Full Text] [Related]

  • 8. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.
    Bozkurt A, Basçi NE, Işimer A, Sayal A, Kayaalp SO.
    Eur J Drug Metab Pharmacokinet; 1996 May; 21(4):309-14. PubMed ID: 9074895
    [Abstract] [Full Text] [Related]

  • 9. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS.
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [Abstract] [Full Text] [Related]

  • 10. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
    Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Béréziat G, Jaillon P.
    J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
    Hu OY, Tang HS, Lane HY, Chang WH, Hu TM.
    J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
    [Abstract] [Full Text] [Related]

  • 18. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 19. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM, Atchison BA, Somogyi AA, Drummer OH.
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract] [Full Text] [Related]

  • 20. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.
    Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B.
    Ther Drug Monit; 1992 Feb; 14(1):1-8. PubMed ID: 1546384
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.